Skip to content

BioMarin plans to start Phase 3 in fall for hemophilia A gene therapy

July 12, 2017
  • BioMarin Provides BMN 270 Data at International Society on Thrombosis and Haemostasis (ISTH) 2017 Congress
  • Initiation of Phase 3 Registrational Study Planned for Q4 2017 with 6e13 vg/kg Dose
  • 97% Reduction in Mean Annualized Bleed Rate (ABR) with 6e13 vg/kg Dose Compared to Prophylaxis
  • 94% Reduction in Mean Annual Factor VIII Infusions with 6e13 vg/kg Dose Compared to Prophylaxis
  • Gene Therapy Facility in U.S. Constructed
  • Conference Call and Live Webcast Tuesday, July 11th at 2:30pm CEST/8:30am ET

http://bit.ly/2tHlpUU

Advertisements

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: